scispace - formally typeset
Journal ArticleDOI

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.
About
This article is published in The Lancet.The article was published on 2002-03-23. It has received 5380 citations till now. The article focuses on the topics: Angiotensin II & Atenolol.

read more

Citations
More filters
Journal ArticleDOI

Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.

TL;DR: This hypothesis provides evidence that AII plays an important role in the prevention of stroke, and certain ARBs like losartan, and telmisartAn, irbesartan and candesartan possess additional properties which may play a role in stroke prevention, which is independent of AII.
Journal ArticleDOI

Homocysteine, B-vitamin supplementation, and stroke prevention: from observational to interventional trials.

TL;DR: The Vitamin Intervention for Stroke Prevention study (VISP) was the first large-scale randomised interventional study that investigated the lowering of homocysteine concentrations with B vitamins in patients with ischaemic stroke and the results were neutral.
Journal ArticleDOI

Hypertension, left ventricular hypertrophy, and sudden death.

TL;DR: This review explores the possible mechanisms behind left ventricular hypertrophy (LVH), a form of end-organ damage in hypertension, and recent studies are addressing whether the latter translates into a prognostic benefit.
References
More filters
Journal ArticleDOI

Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

TL;DR: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Journal ArticleDOI

An updated coronary risk profile. A statement for health professionals.

TL;DR: Using a simple worksheet, a patient's 5- and 10-year CHD risks can be estimated using components of the profile selected because they are objective and strongly and independently related to CHD.
Journal ArticleDOI

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

TL;DR: Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.
Related Papers (5)